Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.
Nasdaq

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with ...
Seeking Alpha

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...
Insider Monkey

Vertex Presents New Data on the Benefits of ALYFTREK

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic ...